Dorsey Wright & Associates purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,505 shares of the company’s stock, valued at approximately $479,000.

Several other hedge funds have also recently made changes to their positions in the company. Jarislowsky Fraser Ltd boosted its position in shares of Zoetis by 13.1% during the 3rd quarter. Jarislowsky Fraser Ltd now owns 194,403 shares of the company’s stock valued at $12,395,000 after acquiring an additional 22,500 shares during the last quarter. Sei Investments Co. boosted its position in shares of Zoetis by 2.7% during the 3rd quarter. Sei Investments Co. now owns 750,960 shares of the company’s stock valued at $47,882,000 after acquiring an additional 20,071 shares during the last quarter. HL Financial Services LLC boosted its position in shares of Zoetis by 16.3% during the 3rd quarter. HL Financial Services LLC now owns 63,758 shares of the company’s stock valued at $4,065,000 after acquiring an additional 8,927 shares during the last quarter. FDx Advisors Inc. boosted its position in shares of Zoetis by 1.6% during the 3rd quarter. FDx Advisors Inc. now owns 54,688 shares of the company’s stock valued at $3,487,000 after acquiring an additional 845 shares during the last quarter. Finally, Global X MANAGEMENT CO LLC boosted its position in shares of Zoetis by 12.4% during the 3rd quarter. Global X MANAGEMENT CO LLC now owns 11,618 shares of the company’s stock valued at $741,000 after acquiring an additional 1,278 shares during the last quarter. 92.44% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Zoetis Inc. (ZTS) traded down $0.25 during trading hours on Tuesday, reaching $68.88. 2,747,400 shares of the company’s stock were exchanged, compared to its average volume of 2,817,065. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. The stock has a market capitalization of $33,686.24, a price-to-earnings ratio of 31.71, a PEG ratio of 2.02 and a beta of 1.02. Zoetis Inc. has a one year low of $48.24 and a one year high of $70.48.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.52 earnings per share. equities analysts forecast that Zoetis Inc. will post 2.36 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be paid a dividend of $0.105 per share. The ex-dividend date is Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a yield of 0.61%. Zoetis’s dividend payout ratio (DPR) is presently 22.11%.

A number of research firms have commented on ZTS. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a research report on Thursday, October 12th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $75.00 target price on shares of Zoetis in a research report on Wednesday, September 6th. BidaskClub cut shares of Zoetis from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Morgan Stanley upped their target price on shares of Zoetis from $61.00 to $70.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $62.00 target price on shares of Zoetis in a research report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $67.06.

ILLEGAL ACTIVITY WARNING: “7,505 Shares in Zoetis Inc. (ZTS) Acquired by Dorsey Wright & Associates” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/14/7505-shares-in-zoetis-inc-zts-acquired-by-dorsey-wright-associates.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.